A practical reference on AOD9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-25. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Pharmacodynamics === 4-HO-NiPT shows affinity for serotonin receptors, including for the serotonin 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7 receptors (Ki = 229–2,461 nM). Conversely, it did not show affinity for the serotonin 5-HT1B or 5-HT5A receptors, whereas the serotonin 5-HT1A receptor was not reported. 4-HO-NiPT is a partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, with EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values of 24 nM (88.4%), 188 nM (69.9%), and 963 nM (45.2%), respectively. It was also a weak agonist of other serotonin receptors, including the serotonin 5-HT1B, 5-HT1E, 5-HT1F, and 5-HT7A receptors (EC50 = 1,400–23,000 nM, Emax = 20.4–123%), but not of the 5-HT1A, 5-HT1D, 5-HT4, 5-HT5A, or 5-HT6 receptors. In contrast to norpsilocin, but similarly to psilocin and certain other N-monoalkyltryptamines like 4-HO-NET, 4-HO-NPT, 4-HO-NALT, and 4-HO-NBnT, the drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It showed 30-fold lower potency than psilocin in this action in mice, but produced about the same maximal response. Similarly to 4-HO-NiPT, other N-monoalkyltryptamines were also much less potent than psilocin, in the range of 10- to 26-fold less potent. In addition to the head-twitch response, 4-HO-NiPT produces hypothermia in rodents. 4-HO-NiPT is a known metabolite of 4-AcO-DiPT and presumably also of 4-HO-DiPT.
Joints are structures that connect individual bones and may allow bones to move against each other to cause movement. There are three divisions of joints: diarthroses, which allow extensive mobility between two or more articular heads; amphiarthroses, which allow some movement; and false joints or synarthroses, which allow little or no movement and are predominantly fibrous. Synovial joints, joints that are not directly joined, are lubricated by a solution called synovial fluid that is produced by the synovial membranes. This fluid lowers the friction between the articular surfaces and is kept within an articular capsule, binding the joint with its taut tissue.
The integration of such columns allows for experiments to be run where materials were in low availability or very expensive, like in biological analysis of proteins. This reduction in reagent volumes allows for new experiments like single-cell protein analysis, which due to size limitations of prior devices, previously came with great difficulty. The coupling of HPLC-chip devices with other spectrometry methods like mass-spectrometry allow for enhanced confidence in identification of desired species, like proteins. Microfluidic chips have also been created with internal delay-lines that allow for gradient generation to further improve HPLC, which can reduce the need for further separations. Some other practical applications of integrated HPLC chips include the determination of drug presence in a person through their hair and the labeling of peptides through reverse phase liquid chromatography.
Sources: en.wikipedia.org
Some proteins are synthesized by nonribosomal peptide synthetases, which can be big protein complexes, each specializing in synthesizing only one type of peptide. Nonribosomal peptides often have cyclic or branched structures and can contain non-proteinogenic amino acids – both of these factors differentiate them from ribosome synthesized proteins. An example of nonribosomal peptides are some of the antibiotics.
They also found that the growth trajectories of BMRP 2002.4.1 and BMRP 2006.4.4 do not fit with other Tyrannosaurus specimens in their growth curve model. While they acknowledged the possibility of these ontogenetically immature specimens representing Nanotyrannus as suggested by Zanno and Napoli (2025), they noted that the inconsistencies of these specimens observed in the growth curve do not necessarily bear weight on the proposal that Nanotyrannus is a distinct taxon. In July 2026, Longrich and colleagues described a third metatarsal bone of perinate (hatchling) Tyrannosaurus rex and cf. Gorgosaurus libratus, RSKM P2416.82 from the Frenchman Formation and TMP 1981.16.475 from the Dinosaur Park Formation respectively. Histological analyses reveal that lines of arrested growth are absent in both specimens, indicative of hatchling or embryonic stage. Synchrotron scans of each specimen reveal the relatively high density of the outer surface and the pattern changes in cortical (outer layer) bone structure, with a layer similar to the hatchling/neonatal line of modern oviparous (egg-laying) and viviparous (giving live birth) taxa that characterize the transition from embryonic to hatchling stage. The scans also detected evidence of Haversian bone remodeling, the continuous process of bone tissue breaking down and rebuilding to form secondary canals (tubular channels connecting bones), which are indicative of hatchling stage and precociality, relative maturity and mobility at birth.
=== Earliest recorded cases === OI has been identified in an ancient Egyptian infant mummified in around 1000 BC, originally dismissed by archaeologists as containing the remains of a monkey. The Norse king Ivar the Boneless, who lived c. 800 CE, is speculated to have had OI as well. Nicolas de Malebranche is often credited as being the first person to describe the physical characteristics of OI in his 1688 book The Search after Truth, in which he describes a man who has had his "bones broken in the places a murderer's would be" all his life. His confident description of the pathology of the disorder, however, which creates what he termed «enfants monstrueux» ("monstrous children"), is scientifically void—he wrote that it was due to the mother's antepartum viewership of a public execution by breaking wheel. The earliest modern scientific studies of OI began in 1788 by Olof Jakob Ekman, who described the condition, which he termed "osteomalacia congenital", in his doctoral thesis and mentioned cases of it going back to 1678, all in the same family, through three generations. Ekman's description of the condition mentioned dwarfism, bone fragility, and bowing of the long bones. In 1831, Edmund Axmann gave a detailed description of it in himself and his two brothers, being the first to mention blue sclerae as a characteristic sign of OI. Jean Lobstein first described the mild form of the condition, today known as type I, in 1833, calling it "osteopsathyrosis idiopathica".
== Predicted properties == Very few properties of rutherfordium or its compounds have been measured; this is due to its extremely limited and expensive production and the fact that rutherfordium (and its parents) decays very quickly. A few singular chemistry-related properties have been measured, but properties of rutherfordium metal remain unknown and only predictions are available.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.